Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).

Tanja HolzheyWolfram PönischSong-Yau WangMadlen HolzvogtBruno HolzvogtMarc AndreaThomas ZehrfeldDoreen HammerschmidtFranz Albert HoffmannCornelia BeckerAndreas SchwarzerMaik SchwarzUta Schönfelder-FrickeThomas EdelmannLeanthe BraunertGeorg-Nikolaus FrankeMadlen JentzschSebastian SchwindMarkus BillJuliane GrimmYvonne RemaneUwe PlatzbeckerMarkus Scholz

Published in: Journal of cancer research and clinical oncology (2021)

These results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment.

Keyphrases

newly diagnosed
multiple myeloma
end stage renal disease
ejection fraction
peritoneal dialysis
combination therapy
patient reported
replacement therapy